ID   HCC4011-GR-step
AC   CVCL_S702
DR   cancercelllines; CVCL_S702
DR   Cosmic; 1896432
DR   Wikidata; Q54881733
RX   PubMed=23542356;
CC   Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (from parent cell line).
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_S700 ! HCC4011
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 11
//
RX   PubMed=23542356; DOI=10.1158/0008-5472.CAN-12-4136; PMCID=PMC4506773;
RA   Shien K., Toyooka S., Yamamoto H., Soh J., Jida M., Thu K.L.,
RA   Hashida S., Maki Y., Ichihara E., Asano H., Tsukuda K., Takigawa N.,
RA   Kiura K., Gazdar A.F., Lam W.L., Miyoshi S.;
RT   "Acquired resistance to EGFR inhibitors is associated with a
RT   manifestation of stem cell-like properties in cancer cells.";
RL   Cancer Res. 73:3051-3061(2013).
//